• For investors wondering whether Enovis stock is starting to look like value or just looks cheap for a reason, this article walks through the key numbers so you can judge the price for yourself.
• After a recent 6.2% gain over the past week and a 1.5% rise over the past month, the stock still sits lower for the year to date, with a decline of 6.5%, and is down 32.2% over the past year, 56.7% over three years, and 67.3% over five years.
• Recent coverage has focused on how Enovis fits within the broader medical equipment sector and how investors are reassessing companies with similar profiles. This helps frame these sharp multi year share price declines and matters because sentiment shifts often show up in valuation ratios long before they appear in the underlying business metrics.
• On Simply Wall St's valuation checks, Enovis scores a 5 out of 6. The next sections break down what different valuation approaches say about that score and point to an even richer way to understand value at the end of the article.

Approach 1: Enovis Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of a company’s future cash flows and discounts them back to today using a required rate of return, giving an estimate of what the business might be worth on a per share basis.

For Enovis, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $52.3 million. Analyst projections supplied to the model go out to 2028, where free cash flow is expected at $178 million. Simply Wall St then extrapolates further cash flows through 2035 using gradually moderating growth assumptions.

Discounting this stream of projected cash flows in dollars back to today produces an estimated intrinsic value of $53.31 per share. Compared with the current share price, this implies Enovis is trading at a 53.5% discount to the DCF estimate. On this model alone, the stock appears to be undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Enovis is undervalued by 53.5%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.

Approach 2: Enovis Price vs Sales

For companies where earnings are not a clear guide, the P/S ratio can be a useful way to value the stock, because it compares what investors are paying for each dollar of revenue rather than each dollar of profit.

Growth expectations and risk still matter here, since faster and more reliable revenue growth usually justifies a higher P/S, while more uncertainty can point to a lower “normal” multiple.

Enovis currently trades on a P/S of 0.63x, compared with the Medical Equipment industry average of 2.75x and a peer group average of 4.15x. On these simple comparisons, the stock sits well below both benchmarks.

Simply Wall St’s Fair Ratio is a proprietary estimate of what P/S multiple might make sense for Enovis given factors such as its earnings growth profile, industry, profit margin, market cap and risk characteristics. Because it is tailored to the company, this Fair Ratio of 1.82x can often be more informative than a broad industry or peer average, which may include very different business models and risk levels.

Comparing the Fair Ratio of 1.82x with the current 0.63x P/S suggests Enovis trades below that customised reference point.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Enovis Narrative

Earlier the article mentioned that there is an even better way to understand valuation. Meet Narratives, which let you attach a clear story about Enovis to the numbers by linking your view of its future revenue, earnings and margins to a financial forecast and a Fair Value estimate that you can compare directly to the current share price.

On Simply Wall St’s Community page, Narratives are available as an easy tool that many investors already use. They update automatically when fresh information such as news, guidance or earnings is added, so your Enovis view is always anchored to the latest data rather than a static model.

For Enovis, one investor might build a more optimistic Narrative that feels closer to the higher Fair Value assumptions around US$58.00 per share, while another might prefer a cautious Narrative nearer US$33.00. By setting up and tracking these side by side you can see exactly which story you agree with and how that translates to a Fair Value that either sits above or below today’s price.

Do you think there's more to the story for Enovis? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.